@article{baf0d125ac5c47e4b215306ad380b7a2,
title = "SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art",
abstract = "Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, {"}Immuno-Oncology Biomarkers: State of the Art,{"} on May 16-17, 2018. Topics discussed included challenges in handling biospecimens, identification and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker development. Panel discussions followed session presentations to help foster participant conversation and discuss future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC Biomarkers Committee.",
keywords = "Biomarkers, Cancer immunotherapy, Checkpoint inhibitor, PD-1/PD-L1",
author = "Butterfield, {Lisa H.} and Disis, {Mary L.} and Fox, {Bernard A.} and Kaufman, {David R.} and Khleif, {Samir N.} and Ena Wang and Helen Chen and Merritt, {William D.} and Sacha Gnjatic and Kara Davis and Ignacio Wistuba and James Lindsay and Stacey Adam and Fred Ramsdell and Smith, {Kellie N.} and Davide Bedognetti and Chen Zhao and Evan Newell and Michael Angelo and David Furman and Marta Luksza and Gherardini, {Pier Federico} and Priti Hegde and Martin Cheever and Steven Fling and Shawn Sweeney and Hongyue Dai and Catharine Young and Kirkwood, {John M.} and Yana Najjar and Randy Sweis and Theresa Lavallee and Maecker, {Holden T.} and Zoe Quandt",
note = "Funding Information: LHB serves on the advisory board for SapVax, Simpatica and Stem Immune. She has also sat in on advisory board meetings for Kite Pharma, Shire and Verastem. MLD has received royalties and has receipt of intellectual property rights from the University of Washington. She has also received research funding from EMD Sorono, Epithany, Pfizer, Janssen, Celegene, Silverback Therapeutics, and holds ownership interests in Epithany. BAF is a co-founder and has ownership in UbiVac. He also receives research support from Bristol-Myers Squibb, Janssen Biotech, Definiens/AstraZeneca, PerkinElmer, Macrogenics, OncoSec, NanoString and Shimadzu. SNK is a board member for Advaxis and Cancer Panels. He is also an advisory member for AstraZeneca, Syndax, Merus BV, IO Biotech, Navigant, Tessa Therapeutics, PDS Biotechnology, BioLine Therapeutics, NewLink Genetics, Bullet BioTech, UbiVac, CanImGuide Therapeutics, Northwest Biotherapeutics, Hikma Pharmaceuticals, CytomX Therapeutics and AratingaBio JNC. DRK did not report any conflicts of interest. EW did not report any conflicts of interest. Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2018",
month = dec,
day = "4",
doi = "10.1186/s40425-018-0453-4",
language = "English (US)",
volume = "6",
journal = "Journal for immunotherapy of cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",
}